Expert Interview
Digging into the positive results from the Phase 3 DeFi trial of Springworks Therapeutics' Nirogacestat in adult patients with progressive desmoid tumors
Ticker(s): SWTXInstitution: MD Anderson
- Professor and Deputy Department Chair of the Department of Sarcoma Medical Oncology at MD Anderson Cancer Center & Chair of the SARC Clinical Research Committee.
- Manages 50 patients with desmoid tumors.
- Research interests include systemic therapy for sarcomas, GISTs and other tumors originating in bone and soft tissues; extensive experience publishing on chemotherapy and targeted therapy and 20+ years experience in rare tumors including malignant pheochromocytoma and paraganglioma.
Roughly how many patients do you manage with desmoid tumors?
Added By: sara_adminWhat were your key take aways from the results of Nirogacestat in the Phase 3 DeFi trial?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Nirogacestat?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
